Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSAhead of the July 23-24 compounding vote, FDA reviewers concluded that none of the seven peptides (BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon) has sufficient evidence for the 503A list, citing missing human data and impurities. Seven of the fourteen panelists who decide have peptide-business ties.
The FDA cleared a single-patient compassionate-use request for Eli Lilly's unapproved triple agonist retatrutide. Eighteen bioethicists and obesity clinicians told STAT the one-person route is the wrong tool for a disease that affects 100 million Americans, when the standard path to the drug is still a clinical trial.
The Pharmacy Compounding Advisory Committee meets July 23 and 24 to decide whether BPC-157, TB-500, MOTS-c, KPV, DSIP, Semax, and Epitalon belong on the 503A list that makes a peptide legal to compound. The seven are voted as one bucket, but their evidence bases are nothing alike.
The TGA made unapproved peptides a 2026 compliance priority and named five: BPC-157, GHK-Cu, TB-500, CJC-1295, and retatrutide. Four have thin human evidence. The fifth is Lilly's Phase 3 obesity drug, swept up because demand outran approval.
On June 19 Japan cleared Wegovy (semaglutide 2.4 mg) for fatty-liver disease with fibrosis, its first approved MASH treatment. The ESSENCE trial cleared inflammation in 62.9 percent of patients versus 34.3 on placebo.
The EMA's first dedicated guideline for synthetic peptide active substances took legal effect on June 1, setting manufacturing and impurity-control standards for the chemistry behind drugs like Wegovy and Mounjaro. It lands as France becomes the first EU country to reimburse them.
A JAMA Viewpoint counts 130,000 Instagram posts and 230 million TikTok views for injectable peptides like BPC-157 and TB-500, and warns the safety research and rules have not caught up. The FDA weighs seven of them for legal compounding on July 23.
The UK's MHRA licensed oral semaglutide 25 mg on June 11, the first GLP-1 weight-loss pill approved by a regulator in Europe. Approval is not access: the tablet is private-only until NICE rules on NHS coverage.
The European Medicines Agency's CHMP on May 22 recommended approval for the once-daily oral Wegovy 25 mg tablet for obesity. The OASIS 4 trial put the pill's mean weight loss at 16.6 percent, in the same range as injectable Wegovy in STEP 1. The label includes SELECT's 20 percent reduction in major heart events, carried over from the injectable. UK, Germany, and Denmark are first in the H2 2026 European launch.
An FDA Adverse Event Reporting System case logged April 30 documenting hepatic failure in a 56-year-old male on Foundayo surfaced May 4, briefly cutting Lilly shares 3% before recovering. The Lilly Global Patient Safety response cited the 11,000-patient ACHIEVE/ATTAIN program with no DILI signal across two years; RBC framed the single case as 'baseline noise, not a mechanistic signal' against class FAERS counts (Ozempic 33, Mounjaro 30, Wegovy 15, Zepbound 2).
The FDA on April 30 proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list, finding 'no clinical need' now that branded supply has stabilized. The proposal forecloses the largest legal pathway for industrial-scale compounded GLP-1 production. Public comment closes June 29, 2026.
An April 29 STAT First Opinion piece argues the FDA's pending peptide reclassifications, driven by HHS Secretary RFK Jr.'s public enthusiasm for BPC-157 and GHK-Cu, risk reopening access to inadequately tested compounds. The op-ed cites three specific safety concerns from the FDA's 2023 Category 2 designations and arrives ahead of the July 23-24 PCAC vote on seven peptides.
A JMCP analysis of 2023 pharmacy claims found that state-level GLP-1 utilization for diabetes tracks diabetes prevalence in commercial plans, but state-level utilization for obesity barely correlates with obesity prevalence. The driver is Medicaid coverage policy, which varies dramatically state-to-state and creates a two-tier access map underneath the federal coverage debate.
Four authors at Emory, Penn, and Ohio State, funded by Arnold Ventures, argue in Nature Medicine that digital twins and in silico clinical trials are arriving in drug development, and that only structured input from regulators and the public sector can make these tools reliable evidence for approval.
CVS/Aetna and UnitedHealth declined to join BALANCE, the insurer-funded Medicare obesity pilot. CMS pivoted: the federal government now directly funds GLP-1 coverage for seniors through the end of 2027.